Original language | English (US) |
---|---|
Pages (from-to) | 255-257 |
Number of pages | 3 |
Journal | Alzheimer Disease and Associated Disorders |
Volume | 32 |
Issue number | 3 |
DOIs | |
State | Published - 2018 |
Externally published | Yes |
Keywords
- Alzheimer's disease
- CSF
- biomarkers
- cortical thickness
- volumetric
ASJC Scopus subject areas
- Clinical Psychology
- Gerontology
- Geriatrics and Gerontology
- Psychiatry and Mental health
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Alzheimer Disease and Associated Disorders, Vol. 32, No. 3, 2018, p. 255-257.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Biomarkers of Cognitive Impairment
AU - Ghazi-Saidi, Ladan
AU - Walsh, Ryan R.
AU - Shan, Guogen
AU - Banks, Sarah J.
N1 - Funding Information: Supported by grant funding from the National Institute of General Medical Sciences (grant: P20GM109025). Data used in the prepa-ration of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). For up-to-date information, see www.adni-info.org. Data collection and sharing for this project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech Inc.; Fujirebio; GE Healthcare; IXICO Ltd; Janssen Alzheimer Immunotherapy Research & Development LLC; John-son & Johnson Pharmaceutical Research & Development LLC; Lumosity; Lundbeck; Merck & Co. Inc.; Meso Scale Diagnostics, LLC; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern Cal-ifornia Institute for Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuroimaging at the University of Southern California.As such, the investigators within the ADNI contributed to the design and imple-mentation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wpcontent/uploads/how_to_ apply/ADNI_Acknowledgement_List.pdf The authors declare no conflicts of interest.
PY - 2018
Y1 - 2018
KW - Alzheimer's disease
KW - CSF
KW - biomarkers
KW - cortical thickness
KW - volumetric
UR - http://www.scopus.com/inward/record.url?scp=85052851821&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85052851821&partnerID=8YFLogxK
U2 - 10.1097/WAD.0000000000000226
DO - 10.1097/WAD.0000000000000226
M3 - Article
C2 - 29189303
AN - SCOPUS:85052851821
SN - 0893-0341
VL - 32
SP - 255
EP - 257
JO - Alzheimer Disease and Associated Disorders
JF - Alzheimer Disease and Associated Disorders
IS - 3
ER -